Kingworld Medicines Group Ltd. (1110) AI Stock Analysis

• Market Cap: HK$339.64M
• Dividend Yield: 6.04%
• Average Volume (3M): 1.31M
• Price to Earnings (P/E): 7.2
• Beta (1Y): 0.18
• Revenue Growth: -3.59%
• EPS Growth: 4.81%
• Country: HK
• Employees: 972
• Sector: Healthcare
• Sector Strength: 54
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 0.08
• Shares Outstanding: 622,499,940
• 10 Day Avg. Volume: 742,400
• 30 Day Avg. Volume: 1,306,666
• PEG Ratio: 1.49
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Kingworld Medicines Group Ltd. scores well due to strong technical indicators and an attractive valuation, with a low P/E ratio and high dividend yield. These factors are somewhat offset by financial performance concerns related to cash flow volatility and liquidity management. The absence of recent earnings call data or notable corporate events means these aspects did not influence the score.

Kingworld Medicines Group Ltd. Business Overview & Revenue Model

Company Description

Kingworld Medicines Group Ltd. is a leading pharmaceutical company engaged in the distribution and marketing of a wide range of healthcare products. The company operates primarily in the sectors of pharmaceuticals and healthcare products, focusing on the distribution of branded pharmaceutical products, proprietary Chinese medicines, and health products. Kingworld is dedicated to providing high-quality healthcare solutions and has established a strong presence in the Asian market.

How the Company Makes Money

Kingworld Medicines Group Ltd. generates revenue through the distribution and sale of pharmaceutical and healthcare products. The company's revenue model is primarily based on its extensive distribution network, which facilitates the supply of both international and domestic healthcare products to a broad customer base, including pharmacies, hospitals, and healthcare institutions. Key revenue streams include the sale of proprietary Chinese medicines and branded pharmaceutical products. Additionally, strategic partnerships with international pharmaceutical brands enhance their product portfolio and contribute significantly to their revenue. Factors such as a strong supply chain, established market presence, and continuous expansion of product offerings play a crucial role in the company's earnings.

Kingworld Medicines Group Ltd. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
1.08B	957.70M	847.39M	745.38M	977.93M
	Gross Profit
280.67M	277.63M	263.60M	280.15M	267.40M
	EBIT
96.81M	72.23M	72.22M	73.65M	76.74M
	EBITDA
125.48M	118.07M	116.00M	120.59M	121.61M
	Net Income Common Stockholders
38.10M	43.54M	51.21M	50.89M	43.43M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
194.03M	256.17M	198.41M	261.46M	128.82M
	Total Assets
1.34B	1.26B	1.21B	1.26B	1.28B
	Total Debt
354.43M	290.68M	238.96M	305.78M	231.82M
	Net Debt
180.75M	48.52M	51.03M	54.96M	118.32M
	Total Liabilities
638.30M	569.15M	493.19M	576.86M	607.18M
	Stockholders Equity
619.03M	615.58M	616.90M	591.80M	603.34M
Cash Flow		Free Cash Flow
-63.25M	93.64M	22.88M	113.66M	112.42M
	Operating Cash Flow
42.28M	186.55M	81.20M	123.58M	132.71M
	Investing Cash Flow
-120.63M	-84.05M	-50.84M	-2.76M	-7.68M
	Financing Cash Flow
4.37M	-51.31M	-87.20M	25.03M	-174.40M

Kingworld Medicines Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.56
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1110, the sentiment is Positive. The current price of 0.56 is above the 20-day moving average (MA) of 0.51, above the 50-day MA of 0.46, and above the 200-day MA of 0.48, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 70.18 is Negative, neither overbought nor oversold. The STOCH value of 62.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1110.

Kingworld Medicines Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1093	76 Outperform	$66.04B	14.33	13.20%	5.99%	-9.60%	-27.18%
1513	74 Outperform	$30.26B	10.46	14.56%	5.68%	-5.37%	6.28%
2318	72 Outperform	$928.26B	6.69		5.69%	11.71%	37.04%
0867	71 Outperform	HK$20.81B	11.79	10.17%	3.99%	-8.91%	-34.40%
1110	70 Outperform	HK$339.64M	7.16	6.61%	6.04%	-3.59%	4.81%
1177	66 Neutral	$68.53B	36.10	6.14%	1.56%	7.63%	-24.23%
Sector *	52 Neutral	$5.21B	3.55	-41.91%	2.83%	15.12%	0.42%

Kingworld Medicines Group Ltd. Corporate Events

Kingworld Medicines Group Ltd. Announces 2024 AGM and Key Resolutions

Kingworld Medicines Group Ltd. has announced its annual general meeting scheduled for May 29, 2025, where shareholders will consider several resolutions, including the adoption of audited financial statements for 2024, the declaration of a final dividend, and the re-election of directors. Additionally, the company seeks approval to issue additional shares, which could impact its market positioning and shareholder value.

Kingworld Medicines Group Ltd. Adopts New Share Award Scheme

Kingworld Medicines Group Ltd. has announced the adoption of the 2025 Share Award Scheme, replacing the 2019 Share Award Scheme, which is set to expire in August 2025. This move is in line with the latest changes to Chapter 17 of the Listing Rules and does not require shareholder approval as it involves existing shares. Additionally, the company has terminated the 2021 Share Option Scheme due to non-compliance with the updated Listing Rules and has no plans to grant further share options under this scheme. The termination of these schemes and the introduction of the new one aim to align with regulatory requirements and optimize the company’s share award strategy.

Kingworld Medicines Group Ltd. Declares Final Cash Dividend for 2024

Kingworld Medicines Group Ltd. has announced a final cash dividend of HKD 0.0317 per share for the financial year ending December 31, 2024. This decision, approved by shareholders on May 29, 2025, reflects the company’s commitment to returning value to its shareholders. The ex-dividend date is set for June 5, 2025, with the payment date scheduled for June 30, 2025. This announcement underscores the company’s stable financial performance and its strategic focus on maintaining shareholder confidence.

Kingworld Medicines Group Ltd. Reports 2024 Annual Results with Increased Profit

Kingworld Medicines Group Ltd. reported its annual results for the year ended December 31, 2024, showing a slight decrease in revenue by 1.6% to approximately RMB1,061,082,000. Despite the decline in gross profit and margin, the company experienced a notable increase in profit before taxation by 1.7% and a significant rise in profit for the year by 20.9% to RMB74,466,000. The board recommended a final dividend of HK3.17 cents per share, pending shareholder approval.

Kingworld Medicines Group Schedules Board Meeting to Review Annual Results

Kingworld Medicines Group Limited has announced a board meeting scheduled for March 28, 2025, in Hong Kong. The meeting’s agenda includes reviewing and approving the audited annual results for the year ending December 31, 2024, and discussing the recommendation of a final dividend, which may impact the company’s financial strategy and shareholder returns.